To investigate the value of this revised technique in testing the efficacy of therapeutics in a preclinical setting, we used a bispecific retargeted antibody based DART® molecule that engages CD19 on leukemia/lymphoma B cells and the TCR on T lymphocytes (14). This evidence concerns the gene CD19 and leukemia.